A Clinically Relevant Pulse Treatment Generates a Bortezomib-resistant Myeloma Cell Line That Lacks Proteasome Mutations and is Sensitive to Bcl-2 Inhibitor Venetoclax

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 27

PMID 35896610

Authors

Sondra L Downey-Kopyscinski

Sriraja Srinivasa

Alexei F Kisselev

Affiliations

Soon will be listed here.

Abstract

Proteasome inhibitors bortezomib and carfilzomib are the backbones of treatments of multiple myeloma, which remains incurable despite many recent advances. With many patients relapsing despite high initial response rates to proteasome inhibitor-containing regimens, it is critical to understand the process of acquired resistance. In vitro generated resistant cell lines are important tools in this process. The majority of previously developed bortezomib-resistant cell lines bear mutations in the proteasome PSMB5 sites, the prime target of bortezomib and carfilzomib, which are rarely observed in patients. Here we present a novel bortezomib-resistant derivative of the KMS-12-BM multiple myeloma cell line, KMS-12-BM-BPR. Unlike previously published bortezomib-resistant cell lines, it was created using clinically relevant twice-weekly pulse treatments with bortezomib instead of continuous incubation. It does not contain mutations in the PSMB5 site and retains its sensitivity to carfilzomib. Reduced load on proteasome due to decreased protein synthesis appears to be the main cause of resistance. In addition, KMS-12-BM-BPR cells are more sensitive to Bcl-2 inhibitor venetoclax. Overall, this study demonstrates the feasibility of creating a proteasome inhibitor resistant myeloma cell lines by using clinically relevant pulse treatments and provides a novel model of acquired resistance.

References

Bajpai R, Sharma A, Achreja A, Edgar C, Wei C, Siddiqa A . Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020; 11(1):1228. PMC: 7060223. DOI: 10.1038/s41467-020-15051-z. View

Tsvetkov P, Detappe A, Cai K, Keys H, Brune Z, Ying W . Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019; 15(7):681-689. PMC: 8183600. DOI: 10.1038/s41589-019-0291-9. View

Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. DOI: 10.1182/blood-2017-06-788786. View

Downey-Kopyscinski S, Daily E, Gautier M, Bhatt A, Florea B, Mitsiades C . An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv. 2018; 2(19):2443-2451. PMC: 6177641. DOI: 10.1182/bloodadvances.2018016360. View

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats J, Stewart A, Reece D . Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013; 24(3):289-304. PMC: 4118579. DOI: 10.1016/j.ccr.2013.08.009. View

Hamilton A, Eder J, Pavlick A, Clark J, Liebes L, Garcia-Carbonero R . Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005; 23(25):6107-16. DOI: 10.1200/JCO.2005.01.136. View

Franke N, Niewerth D, Assaraf Y, van Meerloo J, Vojtekova K, van Zantwijk C . Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 2011; 26(4):757-68. DOI: 10.1038/leu.2011.256. View

Guieze R, Liu V, Rosebrock D, Jourdain A, Hernandez-Sanchez M, Zurita A . Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019; 36(4):369-384.e13. PMC: 6801112. DOI: 10.1016/j.ccell.2019.08.005. View

Kupperman E, Lee E, Cao Y, Bannerman B, Fitzgerald M, Berger A . Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010; 70(5):1970-80. DOI: 10.1158/0008-5472.CAN-09-2766. View

10.

Punnoose E, Leverson J, Peale F, Boghaert E, Belmont L, Tan N . Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016; 15(5):1132-44. DOI: 10.1158/1535-7163.MCT-15-0730. View

11.

Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad E . Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020; 4(5):830-844. PMC: 7065476. DOI: 10.1182/bloodadvances.2019000779. View

12.

Schmidt E, Clavarino G, Ceppi M, Pierre P . SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009; 6(4):275-7. DOI: 10.1038/nmeth.1314. View

13.

Mirabella A, Pletnev A, Downey S, Florea B, Shabaneh T, Britton M . Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol. 2011; 18(5):608-18. PMC: 3134264. DOI: 10.1016/j.chembiol.2011.02.015. View

14.

Kraus M, Bader J, Geurink P, Weyburne E, Mirabella A, Silzle T . The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica. 2015; 100(10):1350-60. PMC: 4591768. DOI: 10.3324/haematol.2014.109421. View

15.

Tao Z, Hasvold L, Wang L, Wang X, Petros A, Park C . Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014; 5(10):1088-93. PMC: 4190639. DOI: 10.1021/ml5001867. View

16.

Cenci S, van Anken E, Sitia R . Proteostenosis and plasma cell pathophysiology. Curr Opin Cell Biol. 2010; 23(2):216-22. DOI: 10.1016/j.ceb.2010.11.004. View

17.

Allmeroth K, Horn M, Kroef V, Miethe S, Muller R, Denzel M . Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. 2020; 35(3):887-892. PMC: 7932915. DOI: 10.1038/s41375-020-0989-4. View

18.

Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin B . Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chem Biol. 2019; 26(3):340-351.e3. DOI: 10.1016/j.chembiol.2018.11.007. View

19.

Lee S, Levitsky K, Parlati F, Bennett M, Arastu-Kapur S, Kellerman L . Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol. 2016; 173(6):884-95. PMC: 5074317. DOI: 10.1111/bjh.14014. View

20.

Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson K, Ploegh H . Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol. 2002; 9(10):1149-59. DOI: 10.1016/s1074-5521(02)00248-x. View